Merck & Co., Inc.

Merck & Co., Inc.

Merck & Co., Inc.

Overview
Date Founded

1891

Headquarters

2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA

Type of Company

Public

Employees (Worldwide)

71K

Industries

Pharmaceuticals
Medical Support Services
Wholesale: Consumer Non-Durables/Sundries
Hospitals & Patient Services
Biotechnology

Company Description

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Contact Data
Trying to get in touch with decision makers at Merck & Co., Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Executive Vice President & Chief Financial Officer

Executive Vice President, Global Services & Chief Financial Officer

Executive Vice President, General Counsel & Corporate Secretary

Executive Vice President, Chief Marketing Officer

Senior Vice President, Human Resources

Executive Vice President, Chief Commercial Officer

Chief Information & Digital Officer

Chief Medical Officer

President-Human Health Europe

Board of Directors

Chief Executive Officer at Merck & Co., Inc.

Chairman, Chief Executive Officer & President at Northrop Grumman Corp.

Executive Chairman at 3M Interamerica, Inc.

Former Managing Partner of Global Business Operations at Accenture Plc

Penn Integrates Knowledge Professor of Population Health & Health Equity at University of Pennsylvania - School of Nursing

Executive Chairman & Founder at BlueVoyant LLC

Chairman & Chief Executive Officer at SARR Group LLC

Former Chief Executive Officer at Nokia of America Corp.

Director-Cardiovascular Genetics Center at The Brigham & Women's Hospital, Inc.

Director at BioFrontiers Institute

Paths to Merck & Co., Inc.
Potential Connections via
Relationship Science
You
Merck & Co., Inc.
Owners & Shareholders
Details Hidden

SSgA FM’s methods of analysis include quantitative, fundamental, technical, cyclical, indexing, arbitrage, charting and other strategy specific methods. They offer a broad range of strategies including: Active, Enhanced, and Passive Equity; Active & Passive Debt; Cash Management; Multi-Asset Class Solutions; Real Estate (including Direct Real Estate); Senior Loans; Managed Futures; and Private Equity. Active equity strategies include enhanced equity and active quantitative strategies. The strategies cover market-cap and style segments of the market including: large-cap core, large-cap growth, large-cap value, mid-cap, small-cap, small-cap value, all-cap, and long-short equity. They also manage long-short and long-short market neutral strategies. SSgA FM’s Active & Passive Debt strategies offers a range of investment styles from passive to active, short to long duration, tax-exempt, sovereign to high yield, and single country to global. The firm’s Cash Management strategies seek to generate current income while preserving capital and liquidity by investing in diversified portfolios of short-term securities. SSgA FM's Multi-Asset Class strategies employ an asset allocation model as means of diversification and seek to position assets among major investment categories. Their Multi Asset Class Solutions strategies employ an asset allocation model as a method of diversification that aims to position assets among major investment categories. SSgA FM’s Managed Futures strategy allocates assets using two approaches: a managed futures strategy and a fixed income strategy. The firm’s Private Equity strategies focus on rigorous partner selection, thorough evaluation of quality investment opportunities, and fundamental, research-driven research.

Details Hidden

JCM seeks to add value versus benchmarks by actively pursuing alpha generation through their own intensive fundamental research for their fundamental investment strategies. They look for companies possessing the firm’s key investment criteria through proprietary research that emphasizes contact with a company’s management team, competitors, suppliers and consumers, as well as in-depth and ongoing financial modeling. Holdings are generally selected one at a time with all other factors (industry, sector, country and cash allocations) being a residual of the investment process. JCM favors businesses that their research reveals have sustainable, above-average earnings growth potential and outstanding free cash flow generation, recurring revenue, profit margins and return on invested capital for their equity strategies. To build a mosaic of information in an effort to identify macro trends and inform allocations across fixed income sectors, the firm uses fundamental credit research.

Details Hidden

WMC relies on their extensive independent research and include portfolio management styles and approaches in equities, fixed income securities, currencies and commodities, as well as asset allocation across these categories. The firm has a number of different disciplines when approaching research and these include asset allocation analysts, currency analysts, data scientists, factor analysts, fixed income credit analysts, fixed income market analysts, global industry analysts and research associates, macro-analysts, quantitative analysts and technical analysts. WMC’s portfolio management teams often include dedicated analysts who evaluate securities and other instruments for suitability based on the team’s investment approach. The firm supplements their internal research with external research from sources such as broker/dealers and third-party research firms. These sources typically provide data, research and analysis and may serve as a gauge of market consensus.

Recent Transactions
Details Hidden

Merck & Co., Inc. purchases Themis Bioscience GmbH

Details Hidden

Fareva SA purchases Msd France SAS /Drug Prodcution Activity from Merck & Co., Inc.

Details Hidden

MH Sub I LLC, WebMD Health Corp. purchase The StayWell Co. LLC from Vestar Capital Partners, Inc., Merck & Co., Inc.

Insider Transactions
Details Hidden
Transaction Advisors
Legal Advisor

Advised onMerck & Co., Inc. purchases Schering-Plough Corporation

Legal Advisor

Advised onMerck & Co., Inc. purchases Schering-Plough Corporation

Investment Advisor

Advised onMerck & Co., Inc. purchases Schering-Plough Corporation

Legal Advisor

Advised onMerck & Co., Inc. purchases Schering-Plough Corporation

Legal Advisor

Advised onMerck & Co., Inc. purchases Schering-Plough Corporation

Legal Advisor

Advised onMerck & Co., Inc. purchases Schering-Plough Corporation

Advisors & Consultants
Legal Advisor

Senior Vice President, General Counsel & Secretary at General Electric Company

Advisor

Chairman at The Stagwell Group LLC

Legal Advisor

Partner at Jones Day

Clients

Henry Schein, Inc., a FORTUNE 500® company and a member of the NASDAQ 100® Index, is the largest provider of health care products and services to medical, dental, and veterinary office-based practitioners. The Company is one of Fortune Magazine's "World’s Most Admired Companies", and is ranked number 1 in its industry in social responsibility and global competitiveness. Now more than ever, health care providers require specialized products and services to operate their practices efficiently. We offer an extensive selection of dental supplies, medical supplies, pharmaceuticals, vaccines, equipment, software technology, and much more. Our portfolio of practice solutions is designed to support our customers and to successfully meet their business goals and achieve optimal patient satisfaction

Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded by Benjamin J. Shaw in 2014 and is headquartered in Portland, ME.

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Founder at Intellia Therapeutics, Inc.

Key Stats and Financials As of 2019
Market Capitalization
$200B
Total Enterprise Value
$252B
Earnings Per Share
$3.82
Revenue
$46.6B
Net Profit
$9.84B
EBITDAMargin
36.46%
Enterprise Value Sales
5.4x
Enterprise Value EBITDAOperating
14.76x
TEVNet Income
25.57x
Debt TEV
0.11x
Total Equity
$26B
EBITDA
$17B
Total Debt
$27.4B
Three Year Compounded Annual Growth Rate Of Revenue
5.66%
Non-Profit Donations & Grants
$1 - $499
2019
$1,000 - $4,999
2019
Political Donations
$1,000
2014
$1,000
2014
$500
2014
Investments
Details Hidden

Just Biotherapeutics, Inc. operates as biotechnology firm. Its products include biosimilars and novel and repositioned biologics. The firm also offers molecular design, process and product platform and manufacturing and plant design services. The company was founded by James N. Thomas, Victor P. Fung, Dean K. Pettit, and Yining Zhao in 2014 and is headquartered in Seattle, WA.

Details Hidden

Yumanity Therapeutics, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Cambridge, MA.

Details Hidden

HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA.

Investors
Details Hidden

Investor at Fluidigm Corp.

Suppliers
Codexis, Inc. Chemicals | Redwood City, CA

Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Johnson & Johnson Personal Products | New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Bayer AG Medical Support Services | Leverkusen, Deu

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Awards & Honors
Rank #72
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #72
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Merck & Co., Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Merck & Co., Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Merck & Co., Inc..